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Diagnosis of post-kala-azar dermal leishmaniasis (PKDL), caused by Leishmania donovani, is difficult, as the
dermal lesions are of several types and resemble those caused by other skin diseases, especially leprosy. Since
the disease generally appears very late after the clinical cure of kala-azar in India, it is also difficult to correlate
PKDL with a previous exposure to L. donovani. Very few attempts have been made so far to diagnose PKDL
serologically, and the diagnostic methods vary in their sensitivities and specificities. Diagnosis of PKDL
through sophisticated PCR methods, although highly sensitive, has limited practical use. We have developed
a serodiagnostic method using an enzyme-linked immunosorbent assay to detect specific immunoglobulin (Ig)
isotypes and IgG subclass antibodies in the sera of Indian PKDL patients. Our assay, which uses L. donovani
promastigote membrane antigens, was 100% sensitive for the detection of IgG and 96.7% specific for the
detection of IgG and IgG1. Optical density values for individual patients, however, demonstrated wide varia-
tions. Western blot analysis based on IgG reactivity could differentiate patients with PKDL from control
subjects, which included patients with leprosy, patients from areas where kala-azar is endemic, and healthy
subjects, by the detection of polypeptides of 67, 72, and 120 kDa. The recognition patterns of the majority of
serum samples from patients with PKDL were also distinct from those of the serum samples from patients with
visceral leishmaniasis (VL), at least for a 31-kDa polypeptide. To further differentiate patients with PKDL
from those with active and cured VL, we analyzed the specific titers of the Ig isotypes and IgG subclasses. High
levels of IgG, IgG1, IgG2, and IgG3 antibodies significantly differentiated patients with PKDL from patients
cured of VL. The absence of antileishmanial IgE and IgG4 in patients with PKDL differentiated these patients
from those with active VL. These results imply intrinsic differences in the antibodies generated in the sera from
patients with PKDL and VL.
Human visceral leishmaniasis (VL), or kala-azar, is a sys-
temic fatal disease caused by an intracellular protozoan para-
site belonging to the Leishmania donovani complex. The par-
asite infects and multiplies preferentially in the macrophages
of the spleen, liver, bone marrow, and lymph nodes of the host.
Post-kala-azar dermal leishmaniasis (PKDL) appears as a der-
matotropic form of the infection of this parasite as a sequel to
kala-azar in 50% of the cases in Sudan and 10 to 20% of the
cases in India (37, 57). In Sudan and other East African coun-
tries, patients develop PKDL during or within 6 months after
treatment for VL (9, 31, 57). In India the disease occurs be-
tween 1 and 7 years after the cure of kala-azar, although longer
periods of 20 to 30 years have also been reported (39, 55). In
8 to 20% of patients the disease may appear without an in-
stance of previous symptomatic kala-azar (37, 55). The clinical
manifestations seen in patients with PKDL are an erythema-
tous rash, predominantly on the face; hypopigmented patches
or macules which may spread over the whole body; or forma-
tions of papules, nodules, or plaques or all possible combina-
tions of these (19, 32, 37). Prolonged treatment regimens with
sodium antimony gluconate (SAG) are generally necessary,
compounding the problems of cost, toxicity, and resistance
associated with this first-line drug used for the treatment of VL
(11, 50). Since kala-azar is anthroponotic in India, patients
with PKDL are considered a reservoir of parasites, which plays
an important role in interepidemic periods of VL (52, 56).
Thus, for the control of VL, reliable diagnostic tests for the
detection of PKDL deserve urgent attention.
Diagnostic methods based on the detection of parasites in
skin smears are invasive and have low sensitivities, especially
for macular lesions, where parasites are scanty (14, 56). PCR
has a better sensitivity than microscopy for the detection of
parasites in skin lesions (34, 46), but its utility is restricted to
well-equipped laboratories. The diagnosis of PKDL is there-
fore made clinically by the distribution and the appearance of
the lesions, along with the temporal association with VL and a
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history of VL (38, 57). PKDL, however, may occur after a long
gap of recovery from VL (30, 39) and even without a prior case
of symptomatic kala-azar (12, 37), compounding the problems
of diagnosis. Moreover, since the lesions of PKDL resemble
those that occur with a large number of skin conditions that
occur in the area, differentiation of PKDL from other condi-
tions, especially leprosy, has proved difficult (8, 40, 57).
In recent years major advances have been made in the de-
velopment of diagnostic methodologies that focus on evalua-
tion of the patient’s antibody response to determine whether
infection or exposure has taken place. Serological tests, includ-
ing direct agglutination tests and enzyme-linked immunosor-
bent assays (ELISAs) based on crude or recombinant antigens,
are highly sensitive (90%) for the diagnosis of VL (27, 43,
53). On the other hand, serological tests for the diagnosis of
PKDL demonstrate various sensitivities and specificities (10,
45). These tests are based on the detection of antileishmanial
immunoglobulin G (IgG) antibodies, which may persist for
years after recovery from VL (25, 54). It is therefore difficult to
differentiate a positive test result for suspected PKDL from a
previous case of VL, limiting the value of these methods in
areas of endemicity. Recent studies investigating the patho-
genic significance of leishmanial antigen (LAg)-specific Ig iso-
types and IgG subclasses have revealed variations in the diag-
nostic sensitivities and specificities of these antibodies in the
sera of patients with kala-azar (2, 4, 6, 43). The levels of these
isotypes are significantly elevated during disease and undergo
a differential decline following resolution of the infection (3, 4,
6). Furthermore, the antigen-specific pattern of isotype reac-
tivity of sera from patients with kala-azar (41, 48) indicates the
potential utility of these isotypes not only for the diagnosis of
kala-azar but also for monitoring of the effectiveness of treat-
ment for kala-azar. The purpose of the present study was to
explore the extension of this concept for the specific diagnosis
of PKDL in comparison to other skin diseases and to differ-
entiate PKDL from active and cured VL.
MATERIALS AND METHODS
Study subjects. Twenty-three Indian patients, mostly from Bihar, who had
suspected PKDL and who were admitted to the School of Tropical Medicine,
Calcutta, India, between 1999 and 2003 were included in this study (Table 1). All
except one of the patients had a history of kala-azar. The time that had elapsed
after cure of kala-azar ranged from 1 to 20 years. Diagnosis of PKDL was done
by clinical examination of the lesions, determination of a history of kala-azar and
residence in an area of endemicity, and other clinical parameters. Three of these
patients had hypopigmented macular lesions, while the rest showed a generalized
presentation of papules, nodules, and plaques, indicating a polymorphic distri-
bution. Except for the patients with macular lesions, the infection was confirmed
by positive slit smears of the lesions and node biopsy specimens. Blood samples
were collected before the initiation of chemotherapy with SAG. For comparison,
10 kala-azar patients who came from Bihar and who were admitted to the same
hospital were also included in this study. Blood from these patients was obtained
before the initiation of chemotherapy and after successful treatment with SAG
(20 mg/kg of body weight). Thirty individuals were included as controls. Of these
individuals, 25 lived in Calcutta and had no history of kala-azar. They consisted
of 10 patients with clinically confirmed leprosy; 5 patients with different skin
diseases, like ringworm, sarcoidosis, skin patches, petyriasis rosea, and erythema
multiforme; and 10 healthy controls from the Indian Institute of Chemical
Biology (IICB). In addition, sera from five healthy controls from Bihar, an area
where VL is endemic, were sampled with the kind help of Shyam Sundar. Sera
were collected from these patients before chemotherapy. This study was ap-
proved by the Ethical Committee on Human Subjects at IICB. Consent for blood
sampling was obtained from all patients and donors.
Antigen preparation. L. donovani AG83, originally isolated from an Indian
kala-azar patient, was cultured in vitro for antigen preparation, as described
earlier (1). Briefly, stationary-phase promastigotes, harvested after the third or
fourth passage, were washed four times in ice-cold 20 mM phosphate-buffered
saline (PBS; pH 7.2) and suspended at a concentration of 1.0 g of cell pellet (2.5
 1010 stationary-phase promastigotes) in 50 ml of cold 5 mM Tris-HCl buffer
(pH 7.6). The suspension was vortexed six times for 2 min each time, with a
10-min interval on ice between each vortexing, and centrifuged at 2,310  g for
10 min. The crude ghost membrane pellet thus obtained was resuspended in 10
ml of the same Tris buffer and sonicated three times for 1 min each time on ice
in an ultrasonicator. The suspension was finally centrifuged at 5,190  g for 30
min, and the supernatant containing the LAgs was harvested and stored in
aliquots at 70°C until use. The amount of protein obtained from 1.0 g of cell
pellet, as assayed by the method of Lowry et al. (28), was 16 mg.
ELISA for parasite-specific Igs. The LAg-specific ELISA for the detection of
IgG, IgM, IgA, IgE, and IgG subclass antibodies was carried out on polystyrene
round-bottom microtiter plates (Tarsons, Calcutta, India), as described earlier
(2). The plates were coated with 100 l of 20 g of LAg per ml in 20 mM
phosphate buffer (pH 7.5) at 4°C overnight. The plates were then washed three
times with PBS supplemented with 0.05% Tween 20. Excess reactive sites were
blocked with 1% bovine serum albumin (BSA) for 3 h at room temperature; and
the plates were washed as described above and subsequently incubated overnight
at 4°C with sera from patients with PKDL, patients with active and cured VL, and
the other controls that had been serially diluted in PBS containing 1% BSA.
After the plates were washed, peroxidase-conjugated goat polyclonal antibody
directed against human IgG, IgM, IgA, and IgE (Sigma Immunochemicals, St.
Louis, Mo.) was applied at a 1:5,000 dilution with PBS for 3 h at room temper-
ature. After four washes, o-phenylenediamine dihydrochloride was applied as the
TABLE I. Study subjects
Subject No. ofsubjects Age (yr [mean  SD])
History of
kala-azara
Lesion, lymph node, or splenic
aspirate biopsy specimen available
PKDL patients
Polymorphic 20 37.52  7.50 20/20 20/20
Macular 3 31.00  18.08 2/3 0/3
Kala-azar patients
Pretreatment 10 28.40  23.80 10/10
Posttreatment 10
Leprosy patients 10 45.20  3.49 0/10
Patients with other skin diseases 5 36.60  13.05 0/5
Healthy controls 10 26.60  1.07 0/10
Controls from areas of endemicity 5 43.00  5.24 0/5
a Data represent the number of subjects with the indicated characteristic/total number of subjects in the group.
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enzyme substrate and the optical density (OD) was read at 450 nm in an ELISA
reader.
For the determination of human IgG subclass antibodies, the LAg-coated
wells, incubated with serially diluted sera, were treated with mouse anti-human
IgG subclass-restricted monoclonal antibodies (Sigma Immunochemicals) at a
1:2,500 dilution overnight at 4°C. After three washes, peroxidase-conjugated goat
anti-mouse IgG (Sigma Immunochemicals) was applied at a 1:5,000 dilution for
3 h at room temperature. The color reaction was carried out as described above,
and the OD at 450 nm was measured. Each serum sample was titrated at the
dilution required to reach half-maximal absorbance (A450  1.0).
SDS-PAGE and Western blotting. The LAgs (6 g/lane) were subjected to
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) on a
10% polyacrylamide gel in a Mini-Protean II apparatus (Bio-Rad Laboratories,
Richmond, Calif.). The resolved proteins were electrophoretically transferred to
nitrocellulose membranes (Bio-Rad) in 20 mM Tris-HCl–190 mM glycine–20%
(vol/vol) methanol buffer at 85 V/cm for 90 min in a Transblot apparatus (Bio-
Rad). The nitrocellulose strips were then blocked overnight at room temperature
in 100 mM Tris-buffered saline (TBS; pH 7.6) containing 0.1% Tween 20 (elec-
trophoresis reagent; Sigma).
Immunoblotting. A minor modification of the immunoblotting procedure out-
lined by Rolland-Burger et al. (42) was used to detect LAg-specific antibodies in
the patient sera. The strips were washed once in washing buffer (100 mM TBS,
0.05% Tween 20) and then incubated with diluted serum samples (1:100 in
washing buffer) for 1 h at room temperature with constant stirring. The samples
included sera from patients with PKDL and leprosy, healthy individuals from
IICB who were never exposed to an area of endemicity, and the individuals from
regions of endemicity. After incubation with the primary antibody, the strips
were washed three times for 20 min each time with washing buffer. After the last
wash, goat anti-human IgG conjugated with peroxidase (Genei, Bangalore, In-
dia) diluted in washing buffer (1:1,000) was added and the mixture was incubated
for 1 h. The strips were then washed thrice, as described above. The last wash was
done without Tween 20. The membranes were developed for 2 to 3 min with a
3,3-diaminobenzidine tetrahydrochloride (DAB) substrate (Sigma) dissolved in
100 mM TBS (0.05% DAB, 0.015% H2O2). With the onset of color development,
the reaction was stopped by rinsing with double-distilled H2O several times.
Statistical analysis. Data were compared for statistical significance by the
two-tailed unpaired Student’s t test and nonparametric Mann-Whitney test with
Graphpad Prism software. P values of 	0.05 were considered significant. The
lower limit of positivity (the cutoff) was determined from the mean of the healthy
controls  2 standard deviations at a dilution of 1:900 (13).
RESULTS
Specific antibody responses of Indian PKDL patients. In
this study, 53 serum samples, including 23 serum samples from
patients with PKDL, 10 serum samples from healthy controls,
5 serum samples from controls from areas of endemicity, 10
serum samples from patients with leprosy, and 5 serum sam-
ples from patients with other skin diseases (Table 1), were
tested for their antileishmanial antibody responses to the
membrane antigens prepared from L. donovani promastigotes
(LAgs). Figure 1 and Table 2 show the performances of the
sensitivities and the specificities of the ELISAs with sera from
patients with PKDL through the responses of the IgG, IgM,
IgA, IgE, and IgG subclasses. The reactivities of the IgG, IgA,
and IgG subclass antibodies from the sera of patients with
PKDL with LAg were significantly higher than those of the
sera from the controls, including healthy controls, controls
from areas of endemicity, and patients with leprosy and other
skin diseases (P 	 0.0003). The sera were applied at a 1:900
dilution, and the results are represented in an x-y scatterplot
(Fig. 1). Among all the Ig isotypes, the IgG response was the
best, with the IgG ELISA showing a 100% sensitivity, followed
by the IgG1 ELISA (sensitivity, 90.90%). ELISAs for these two
antibodies also showed the highest specificity (96.7%) (Table
2), with a cross-reaction to both antibodies by only one serum
sample from a patient with leprosy (Fig. 1). ELISAs for the
LAg-specific IgA, IgG3, and IgG4 responses of PKDL patients
were moderately sensitive (86.4, 81.8, and 86.4%, respectively);
but their specificities were comparatively lower (50, 83.3, and
53.4%, respectively). The highest cross-reactivity was observed
with sera from patients with leprosy. All of the serum samples
from patients with leprosy had cross-reactive IgA and IgG4
responses to LAg, and 50% of the serum samples from patients
with leprosy had cross-reactive IgG3 responses with LAg, with
OD values just above the cutoff. ELISAs for IgM and IgG2 had
lower sensitivities than those for the other isotypes, and the
sera from patients with leprosy had considerable cross-reactive
IgM responses to LAg. In comparison to the other isotypes,
IgE in sera from patients with PKDL showed an absolute
absence of an LAg-specific response and no cross-reaction with
the other control sera.
Western blot profiles in response to LAg. Even though our
ELISA was 100% sensitive, it showed low ODs for some PKDL
patients, which might cause diagnostic confusion, especially
confusion with leprosy. To improve the differentiation of pa-
tients with PKDL serologically from patients with leprosy, in-
dividuals who live in an area of endemicity, and other healthy
controls, we selected 4 samples each from patients with lep-
rosy, controls who lived in an area of endemicity, and healthy
controls and 23 serum samples from patients and tested them
for their IgG reactivities to SDS-PAGE-separated polypep-
tides of LAg transferred onto nitrocellulose. The comparative
IgG reactivity patterns of these samples are shown in Fig. 2.
The LAg-specific pattern of recognition varied for the sera
from the PKDL patients, depending on the reactivity of each
serum sample, but these patterns were clearly distinct from
those for the sera of patients with leprosy, healthy controls,
and controls who lived in areas of endemicity. Despite the
heterogeneous response to LAg, eight polypeptides with rela-
tive molecular masses of 51, 55, 63, 67, 72, 78, 91, and 120 kDa
were reactive with 95.7 to 100% of the serum samples from
patients with PKDL. In addition, major bands of 34 kDa
(78%), 155 kDa (74%), 36 kDa (69.6%), 47 and 145 kDa
(65%), 43 and 57 kDa (52%), and 39, 97, and 190 kDa (48%)
were frequently recognized. While most of these frequently
recognized bands were also reactive with sera from patients
with kala-azar and patients who had been cured of kala-azar
(Fig. 2B) (41), differences in reactivity were observed for the
31- and 67-kDa polypeptides. Although the 31-kDa polypep-
tide was not recognized by 82.6% of the serum samples from
patients with PKDL, it was recognized by 100% of the serum
samples from patients with VL and 73 to 100% of the serum
samples from patients cured of VL (Fig. 2B) (41). Conversely,
the 67-kDa polypeptide, which was recognized by 100% of the
serum samples from patients with PKDL, was recognized by
only 6.7% (41) to 20% (Fig. 2B) of the serum samples from
patients with VL before and after treatment. Among the con-
trols, very faint cross-reactions were observed, mostly to the
63-kDa (100%) and 145-kDa (75%) peptides for the sera from
patients with leprosy, the 63-kDa peptide (75%) for the sera
from healthy individuals, and the 91- and 78-kDa peptides
(75%) and the 63- and 55-kDa peptides (100%) for the sera
from the controls from areas of endemicity (Fig. 2C).
Differential diagnosis of PKDL from active and cured VL.
To differentiate PKDL serologically from untreated and cured
VL, a clinical study was undertaken with Indian kala-azar pa-
VOL. 43, 2005 SERODIAGNOSIS OF PKDL 1271
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FIG. 1. LAg-specific antibody reactivities (absorbances) of sera from patients with PKDL, healthy controls (HC), controls from areas of
endemicity (EC), patients with other skin diseases (OSD), and patients with leprosy (Lep). The horizontal bars represent the means for the
different groups. The dotted lines indicate the cutoff value (the mean for the healthy controls  2 standard deviations).
1272 SAHA ET AL. J. CLIN. MICROBIOL.
 o
n
 July 23, 2014 by guest
http://jcm.asm.org/
D
ow
nloaded from
 
tients by using the titers of LAg-specific Ig isotype and IgG
subclass antibodies (Fig. 3). The intergroup differences were
analyzed by the nonparametric Mann-Whitney test. Although
high levels of anti-LAg IgG, IgM, IgA, IgG1, IgG2, and IgG3
antibodies were observed in the sera of PKDL patients, the
titers of the IgG, IgM, IgE, and IgG4 antibodies in patients
with the active stage of kala-azar were significantly higher (P
0.0011, 0.0029, 	0.0001, and 	0.0001, respectively) than those
in PKDL patients. In contrast to the sera from patients with
active VL, none of the serum samples from patients with
PKDL showed an antigen-specific IgE response, and the IgG4
response was very low in 21 of the 23 serum samples from
patients with PKDL tested. This lack of LAg-specific IgE and
IgG4 responses in PKDL patients may help to discriminate
patients with PKDL from those with VL. The titers of anti-
LAg IgG, IgG1, IgG2, and IgG3 antibodies in the sera of
PKDL patients were significantly higher (P  0.0005, 	0.0001,
0.0043, and 0.0005 respectively) than those of the antibodies
that persisted in the patients cured of VL in the past. The level
of IgE, which was low in individuals cured of VL, was signifi-
cantly higher (P  0.0328) in the sera of patients with PKDL.
The specific patterns of the Ig isotype and IgG subclass re-
sponses of the sera from patients with PKDL in comparison to
those of the sera from patients with active and cured VL
suggest that this response is due to the occurrence of PKDL
rather than the persistence of antibodies to VL.
FIG. 2. Western blot analysis of the IgG reactivities with SDS-PAGE-separated (6 g/lane) membrane proteins of LAg of sera from patients
with PKDL (A); kala-azar (VL) (B) before (odd-numbered lanes) and after (even-numbered lanes) treatment; and controls (C), including healthy
controls (lanes 1 to 4), controls from areas of endemicity (lanes 5 to 8), and patients with leprosy (lanes 9 to 12). Each lane represents one serum
sample. The molecular masses of the prominent bands are marked on the left.
TABLE 2. Sensitivities and specificities of IgG, IgM, IgA, IgE, and
IgG subclass ELISAs for PKDL patients
Antibody
(cutoff value) Sensitivity
a (%) Specificitya (%)
IgG (0.275) 100.0 96.7
IgM (0.420) 36.4 83.3
IgA (0.122) 86.4 50.0
IgE (0.315) 0.0 100.0
IgG1 (0.479) 90.9 96.7
IgG2 (0.448) 45.5 93.3
IgG3 (0.254) 81.8 83.3
IgG4 (0.120) 86.4 53.4
a Calculations were done with respect to cutoff OD values for the respective Ig
ELISA.
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FIG. 3. Comparison of LAg-specific IgG, IgM, IgA, IgE, and IgG subclass antibody titers in sera from patients with PKDL with those in sera
from patients with VL before and after treatment. Symbols represent individual patients, and the horizontal bars indicate the median isotype levels
in 10 samples from patients with VL and 23 samples from patients with PKDL. Groups were compared for statistical significance by the
nonparametric Mann-Whitney test.
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DISCUSSION
Parasitological methods have been considered the first
choice for the diagnosis of leishmaniases, including PKDL.
However, demonstration of parasites in skin smears or biopsy
specimens from PKDL patients is hampered by the fact that
lesions occur mainly on the face. Besides, parasites are scanty
and are found in only one-third of the patients (23, 34). Par-
asites are extremely difficult to demonstrate in the hypopig-
mented macuoles, which may be the initial manifestation of
PKDL (6, 28, 46). The disease is therefore often misdiagnosed
as leprosy, a coendemic disease that resembles PKDL both
clinically and pathologically (8, 12, 40). PCR is a sensitive and
specific assay for the diagnosis of PKDL (34, 46). However,
PCR is expensive and requires sophisticated facilities and
trained personnel, restricting its use. Thus, a more economical
and practical assay is required for the sensitive and specific
diagnosis of PKDL.
Given the strong humoral response that accompanies leish-
manial infections, it is not surprising that tests based on sero-
logical techniques have been developed for the diagnosis of VL
(49). In comparison, attempts at the serodiagnosis of PKDL
have been few, and these lack sensitivity and specificity. Anti-
leishmanial antibodies of the IgG, IgM, and IgG subclasses
have been demonstrated in the sera of PKDL patients (18, 21).
However, to our knowledge, determination of the subclass
distribution of the antibody response for the diagnosis of
PKDL has not been investigated. In this study we have evalu-
ated the utility of leishmanial membrane antigen (LAg)-spe-
cific Ig isotypes and IgG subclasses for the specific diagnosis of
PKDL. The sera of a high proportion of the PKDL patients
had elevated levels of anti-LAg IgG, IgM, IgA, and IgG sub-
class (IgG1, IgG2, and IgG3) antibodies. In contrast, the sera
of the patients with PKDL demonstrated an absence of IgE
and low levels of IgG4. The high sensitivities and specificities
of IgG and IgG1 in the LAg-specific ELISA demonstrate the
potential of this assay for the diagnosis of PKDL.
Among the Ig isotype and IgG subclasses studied, IgG
showed the highest sensitivity and specificity for LAg in PKDL
patients. The IgG ELISA conducted with LAg appeared to be
more sensitive than serodiagnosis with whole cells by a direct
agglutination test (35, 57), an IgG ELISA with total parasite
antigen extract (45), as well as a strip test and an IgG ELISA
with recombinant K39 (rK39) antigen (47, 54) and other spe-
cific antigens (13). The sensitivity of the IgG ELISA for LAg
observed in the present study for the diagnosis of PKDL
(100%) was even higher than that reported for PCR in Sudan
(82.7%) (34) and India (93.8%) (46). The specificity of the
assay (96.7%), although lower than those of PCR and the strip
test with rK39 (100%) (46, 47), was higher than the specificities
of ELISAs with promastigote and amastigote antigen extracts
and rK39 (45).
Increases in the sensitivity and specificity of the serodiagno-
sis of PKDL by use of a combination of specific antigens has
been observed earlier (13), indicating the strong potential of
the components of LAg for use in the diagnosis of PKDL.
However, a false-positive reaction with LAg was observed with
a serum sample from a leprosy patient, a disease often con-
fused with PKDL (8, 12, 40, 57). Moreover, the IgG antibody
reactivities of sera from patients with PKDL with LAg, al-
though significantly higher than those of sera from the con-
trols, demonstrated wide variations in IgG absorbance just
above the cutoff value for some specimens. The Western blot
technique is among the most sensitive and specific serological
methods; in addition, it provides information about the para-
site’s antigenic profile (42). We therefore investigated by im-
munoblotting the activities of sera from patients with PKDL in
comparison to those of sera from patients with leprosy and
negative controls. The band patterns of the PKDL patient sera
in this study were consistent, with at least eight immunodom-
inant bands, regardless of the level of IgG reactivity with LAg
in the ELISA. Apart from the 63-kDa polypeptide, none of
these polypeptides showed cross-reactivity with antibodies
from healthy individuals or leprosy patients. A mild cross-
reaction, however, with the 55-, 78-, and 91-kDa polypeptides
was observed with sera from controls from areas of endemicity,
restricting the achievement of 100% sensitivity and specificity
of recognition by PKDL patient sera to reactivities with
polypeptides of 67, 72, and 120 kDa. Of the polypeptides most
frequently recognized by sera from patients with PKDL, all
except the 67-kDa polypeptide were also recognized by the
majority of the serum samples from patients with kala-azar
before and after treatment. Again, a 31-kDa band of LAg
recognized by the majority of the VL patient sera both before
and after treatment showed a lack of reactivity with the ma-
jority of PKDL patient serum samples, demonstrating the po-
tential for the use of these polypeptides for the differentiation
of PKDL from past and ongoing VL infections. Previous in-
vestigations (18, 26, 44) on the host immune response to L.
donovani antigens in PKDL patients report specific reactions
to antigens different from those observed in the present study.
A similar lack of reactivity to an antigen fraction (200 kDa) by
PKDL patient sera but the reactivity of VL patient sera to this
antigen fraction (26) demonstrates that adaptations of these
antigens may be helpful in differentiating PKDL from active
and past VL.
Most serological tests for the diagnosis of PKDL are of
limited value in areas of endemicity, as they are also positive
for kala-azar for patients with active and past cases of kala-azar
(3, 18, 20, 41, 44, 45, 56). Even rK39 ELISA titers remain
positive for up to 2 years after treatment, with no decline in
OD values (54). As a result these tests cannot differentiate
PKDL from active and past kala-azar. Moreover, tests that can
be used to differentiate PKDL from VL are also important for
the conclusive diagnosis of PKDL instead of leprosy in leprosy
patients with a history of VL. Ig isotypes and IgG subclass
antibodies in kala-azar patients demonstrated differential re-
sponses after successful chemotherapy (3, 6), and Ig isotype
and IgG subclass specificities were observed in PKDL patient
sera. Therefore, as an attempt to further differentiate PKDL
from active kala-azar as well as past cases of kala-azar, we
investigated the LAg-specific titers of these antibodies of
PKDL patient sera and compared them with those of sera from
patients with active and cured kala-azar. PKDL could be dif-
ferentiated from active VL by an almost complete absence of
IgE and IgG4. In addition, an elevation of IgG, IgG1, IgG2,
and IgG3 titers in patients with PKDL in comparison to the
negligible levels of these isotypes in individuals cured of VL
could help differentiate PKDL from past VL. Although sera
from leprosy patients with past VL were not evaluated in the
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present study, the ability to differentiate PKDL from both
active and cured VL will also help with the specific diagnosis of
PKDL instead of leprosy in leprosy patients with a history of
VL. Our results reinstate the observation that differentiation of
PKDL from active and past kala-azar cannot be performed
through the analysis of specific IgG levels alone (54). More-
over, a differential Ig isotype profile in patients with PKDL in
comparison to that in patients with active and cured VL, to-
gether with a lack of IgG recognition of the 31-kDa band,
suggest that these antibodies in PKDL are not remnants of
previous exposure to VL but are specific for the dermal dis-
ease.
Interestingly, the IgA responses in PKDL patients appeared
to be reciprocal to the IgE responses in VL patients. While the
significance of these observations has not been investigated in
this study, recent advances suggest the involvement of inter-
leukin-10 (IL-10) and transforming growth factor 
 (TGF-
)
in enhancing IgA production in human cells (7, 29, 33). IL-4
and IL-13 are involved in the induction of IgE (15, 36, 58), and
the presence of IL-10 appears to down regulate the IL-4-
induced IgE levels (24). The IL-4 and IL-10 responses have
been extensively documented in patients with VL (17, 51, 58)
and PKDL. However, higher levels of IL-10 have been re-
ported in patients with PKDL, and higher IL-10 levels are also
predictive of the dermal disease (16, 22). Although TGF-
 has
not been reported so far in patients with PKDL, recent evi-
dence indicates that regulatory T cells characterized by their
ability to produce IL-10 and TGF-
may play an important role
in the reactivation of persistent infections like PKDL (5). It is
therefore tempting to speculate that the decreased levels of
production of IgE and the enhanced production of IgA in
patients with PKDL, reciprocal to the situation in patients with
VL, is due to the activities of IL-10, probably with help from
TGF-
; and this speculation needs to be investigated.
In conclusion, our results demonstrate the use of ELISA and
immunoblotting for the reliable and sensitive diagnosis of
PKDL. The data presented here reveal that differentiation of
PKDL not only from leprosy but also from active and cured VL
is possible. These observations are sufficiently promising to
warrant further validation to determine the potentials of Ig
isotype profiles as markers for the differential diagnosis of
PKDL.
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